Industry
Allievex Corporation
Total Trials
5
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
Failure Rate
0.0%
0 terminated/withdrawn out of 5 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Phase 2
1(33.3%)
Phase 1
1(33.3%)
Phase 4
1(33.3%)
3Total
Phase 2(1)
Phase 1(1)
Phase 4(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (5)
Showing 5 of 5 trials
NCT05492799Phase 4Enrolling By Invitation
Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE
Role: lead
NCT03784287Phase 2Unknown
A Treatment Extension Study of Mucopolysaccharidosis Type IIIB
Role: lead
NCT03227042Unknown
A Prospective Natural History Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)
Role: lead
NCT02754076Phase 1Completed
A Treatment Study of Mucopolysaccharidosis Type IIIB
Role: lead
NCT02493998Completed
A Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)
Role: lead
All 5 trials loaded